BioSmart

At a glance

BioSmart filed 27 disclosures in the last 12 months, including 7 insider, 5 5% holder and 1 buyback. The most recent key filing was on Sep 9.

Revenue for 2025 was ₩483B, down 0.3% on 2024. Operating margin was 4.7% against 4.2% a year earlier. Debt was 65% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩313B and operating profit of ₩15.2B.

The 2025 annual report lists 168 employees with an average tenure of 9.6 years and average pay of ₩57M, #1116 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩397M each on average. It paid no cash dividend for 2025. 박혜린 and related parties held 24.72% at year end.

From the 2025 annual report

Staff: 168 (103 men, 65 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩9.5B. Directors and auditors: 4, paid ₩1.6B in total.

No cash dividend was paid for 2025.

Largest shareholder

박혜린 holds 19.91%; with 3 related parties the group holds 24.72% of common shares at year end.

Individuals paid ₩500M or more

Auditor: 대주회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary